Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.
Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari R, Tardif JC, Tendera M, Greenlaw N, Steg PG; CLARIFY Investigators. Kalra PR, et al. Among authors: tendera m. PLoS One. 2014 Jul 22;9(7):e102335. doi: 10.1371/journal.pone.0102335. eCollection 2014. PLoS One. 2014. PMID: 25051258 Free PMC article.
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group. Rouleau JL, et al. Among authors: tendera m. J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9. doi: 10.1016/j.jacc.2003.11.037. J Am Coll Cardiol. 2004. PMID: 15093878 Free article. Clinical Trial.
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: tendera m. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Resting heart rate in cardiovascular disease.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Fox K, et al. Among authors: tendera m. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. doi: 10.1016/j.jacc.2007.04.079. Epub 2007 Aug 13. J Am Coll Cardiol. 2007. PMID: 17719466 Free article. Review.
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Fox K, et al. Among authors: tendera m. Eur Heart J. 2009 Oct;30(19):2337-45. doi: 10.1093/eurheartj/ehp358. Epub 2009 Aug 31. Eur Heart J. 2009. PMID: 19720635 Clinical Trial.
436 results